001     309875
005     20260217120818.0
024 7 _ |a 10.1016/j.celrep.2026.116975
|2 doi
024 7 _ |a pmid:41678337
|2 pmid
024 7 _ |a 2211-1247
|2 ISSN
024 7 _ |a 2639-1856
|2 ISSN
037 _ _ |a DKFZ-2026-00360
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Ector, Carolin
|b 0
245 _ _ |a Circadian rhythm heterogeneity modulates drug response variations in neuroblastoma models.
260 _ _ |a Maryland Heights, MO
|c 2026
|b Cell Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1771251932_2335468
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #DKTKZFB9#
520 _ _ |a Circadian clocks regulate essential cellular functions and influence cancer development and treatment outcomes. Aligning therapy with circadian rhythms can improve efficacy and reduce toxicity, yet whether neuroblastoma, a heterogeneous pediatric tumor, maintains circadian function remains unclear. Here, we systematically profiled circadian dynamics across 12 neuroblastoma cell models using long-term bioluminescence assays and computational analysis. Our findings reveal heterogeneous circadian patterns ranging from robust to arrhythmic, which we linked to distinct neuroblastoma genetic features. By integrating drug sensitivity data, we identified candidate compounds whose effectiveness correlates with circadian expression profiles. Moreover, time-of-day treatment assays with the ALK inhibitor lorlatinib and frontline chemotherapeutics revealed distinct temporal drug responses that were more pronounced in circadian-competent than weakly rhythmic cell lines. Together, these findings establish circadian heterogeneity as a previously unrecognized dimension of neuroblastoma biology and highlight the therapeutic potential of chronotherapy approaches for improved treatment efficacy.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a CP: cancer
|2 Other
650 _ 7 |a CP: metabolism
|2 Other
650 _ 7 |a cancer
|2 Other
650 _ 7 |a chronotherapy
|2 Other
650 _ 7 |a circadian clock
|2 Other
650 _ 7 |a circadian rhythms
|2 Other
650 _ 7 |a neuroblastoma
|2 Other
650 _ 7 |a systems biology
|2 Other
650 _ 7 |a time-of-day sensitivity
|2 Other
700 1 _ |a Schmal, Christoph
|b 1
700 1 _ |a Didier, Jeff
|b 2
700 1 _ |a De Landtsheer, Sébastien
|b 3
700 1 _ |a Schulte, Johannes H
|b 4
700 1 _ |a Keilholz, Ulrich
|0 P:(DE-He78)db014277a1d4005afd93fa95bc6a1001
|b 5
700 1 _ |a Sauter, Thomas
|b 6
700 1 _ |a Kramer, Achim
|b 7
700 1 _ |a Herzel, Hanspeter
|b 8
700 1 _ |a Granada, Adrián E
|b 9
773 _ _ |a 10.1016/j.celrep.2026.116975
|g Vol. 45, no. 2, p. 116975 -
|0 PERI:(DE-600)2649101-1
|n 2
|p 116975
|t Cell reports
|v 45
|y 2026
|x 2211-1247
909 C O |o oai:inrepo02.dkfz.de:309875
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)db014277a1d4005afd93fa95bc6a1001
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2026
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-10
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL REP : 2022
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2025-08-21T14:50:29Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2025-08-21T14:50:29Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2025-08-21T14:50:29Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-10
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-11-10
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CELL REP : 2022
|d 2025-11-10
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-11-10
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-11-10
920 1 _ |0 I:(DE-He78)BE01-20160331
|k BE01
|l DKTK Koordinierungsstelle Berlin
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)BE01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21